|
humans |
27 |
|
male |
26 |
|
middle aged |
24 |
|
lung cancer |
22 |
|
adult |
19 |
|
female |
18 |
|
aged |
15 |
|
asthma |
14 |
|
bronchiectasis |
14 |
|
chronic obstructive pulmonary disease |
14 |
|
copd |
14 |
|
covid-19 |
14 |
|
obstructive sleep apnea |
13 |
|
body mass index |
12 |
|
covid-19 vaccines |
12 |
|
innate immunity |
12 |
|
tuberculosis |
12 |
|
aged, 80 and over |
11 |
|
cross-sectional studies |
10 |
|
hong kong |
10 |
|
medical sciences |
10 |
|
egfr |
9 |
|
smoking |
9 |
|
bronchiectasis exacerbation |
8 |
|
chemotherapy |
8 |
|
eosinophil |
8 |
|
fatal outcome |
8 |
|
interstitial lung disease |
8 |
|
obesity |
8 |
|
pemetrexed |
8 |
|
phenotype |
8 |
|
prognosis |
8 |
|
adiponectin |
7 |
|
adiponectin - blood |
7 |
|
atherosclerosis |
7 |
|
biomarkers |
7 |
|
body composition - physiology |
7 |
|
cohort studies |
7 |
|
down-regulation - physiology |
7 |
|
early detection |
7 |
|
enzyme-linked immunosorbent assay |
7 |
|
intra-abdominal fat - physiopathology |
7 |
|
lung adenocarcinoma |
7 |
|
magnetic resonance imaging |
7 |
|
molnupiravir |
7 |
|
non-small cell lung cancer |
7 |
|
risk factors |
7 |
|
sleep apnea, obstructive - diagnosis - physiopathology |
7 |
|
subcutaneous fat, abdominal - physiopathology |
7 |
|
sympathetic activity |
7 |
|
sympathetic nervous system - physiopathology |
7 |
|
advanced glycation end-products |
6 |
|
biological markers - analysis |
6 |
|
blood glucose - analysis |
6 |
|
bronchiolitis obliterans syndrome |
6 |
|
c-reactive protein |
6 |
|
c-reactive protein - analysis |
6 |
|
carcinoma, non-small-cell lung - drug therapy |
6 |
|
chemicals and cas registry numbers |
6 |
|
china - ethnology |
6 |
|
disease progression |
6 |
|
egfr mutation |
6 |
|
endothelial function |
6 |
|
gefitinib |
6 |
|
gene expression |
6 |
|
graft versus host disease |
6 |
|
haematopoietic stem cell transplantation |
6 |
|
hong kong - epidemiology |
6 |
|
hospitalization |
6 |
|
intra-abdominal fat |
6 |
|
lung function |
6 |
|
lung function decline |
6 |
|
lung neoplasms - drug therapy |
6 |
|
osimertinib |
6 |
|
polysomnography |
6 |
|
regression analysis |
6 |
|
sensitivity and specificity |
6 |
|
sleep apnea, obstructive - metabolism |
6 |
|
visceral fat |
6 |
|
waist circumference |
6 |
|
acute exacerbation |
5 |
|
acute kidney injury |
5 |
|
adenocarcinoma |
5 |
|
adenocarcinoma - diagnosis - pathology |
5 |
|
age factors |
5 |
|
alk |
5 |
|
amiodarone - adverse effects - analogs and derivatives |
5 |
|
anaplastic lymphoma kinase |
5 |
|
antibiotic agent |
5 |
|
antigens, cd56 - biosynthesis |
5 |
|
autofluorescence bronchoscopy |
5 |
|
azithromycin |
5 |
|
blood pressure |
5 |
|
brain metastasis |
5 |
|
bronchiolitis obliterans syndrome (bos) |
5 |
|
carcinoma, non-small-cell lung - blood - genetics - pathology |
5 |
|
carcinoma, squamous cell - diagnosis - pathology |
5 |
|
carcinoma, squamous cell - diagnosis - therapy - ultrasonography |
5 |
|
chinese |
5 |
|
chronic kidney disease |
5 |
|
coronavirus disease 2019 |
5 |
|
cytological techniques |
5 |
|
dna, neoplasm - blood - genetics |
5 |
|
dronedarone |
5 |
|
egfr array |
5 |
|
endobronchial ultrasound |
5 |
|
endothelial progenitor cells |
5 |
|
epidermal growth factor receptor |
5 |
|
follow-up |
5 |
|
hematopoietic sct (hsct) |
5 |
|
hilar lymphadenopathy |
5 |
|
intermittent hypoxia |
5 |
|
kras |
5 |
|
logistic models |
5 |
|
lung - physiopathology |
5 |
|
lung adenocarcinomas |
5 |
|
lung diseases - chemically induced |
5 |
|
lung neoplasms - diagnosis - pathology |
5 |
|
lung neoplasms - diagnosis - therapy - ultrasonography |
5 |
|
lymph nodes - pathology |
5 |
|
masks |
5 |
|
metabolic syndrome |
5 |
|
metabolic syndrome x - complications - physiopathology |
5 |
|
methylprednisolone |
5 |
|
mutation - genetics |
5 |
|
nirmatrelvir-ritonavir |
5 |
|
nirmatrelvir–ritonavir |
5 |
|
non-small-cell lung cancer |
5 |
|
nsclc |
5 |
|
obstructive sleep apnoea |
5 |
|
oncogenic mutations |
5 |
|
plasma egfr mutations |
5 |
|
prevalence |
5 |
|
prospective studies |
5 |
|
receptor, epidermal growth factor - genetics |
5 |
|
sex factors |
5 |
|
sleep apnea syndromes - complications - physiopathology |
5 |
|
small cell carcinoma |
5 |
|
sputum - cytology |
5 |
|
sputum cytology |
5 |
|
squamous cell carcinoma |
5 |
|
synchronous primary lung cancer |
5 |
|
transbronchial needle aspiration |
5 |
|
tumor markers, biological - blood - genetics |
5 |
|
tyrosine kinase inhibitor therapy |
5 |
|
ultrasonography - methods |
5 |
|
vaccine |
5 |
|
acquired myasthenia gravis |
4 |
|
afatinib |
4 |
|
anthropometry - methods |
4 |
|
antineoplastic agents - therapeutic use |
4 |
|
asia |
4 |
|
asthma control |
4 |
|
asthma exacerbation |
4 |
|
autoimmune |
4 |
|
azathioprine |
4 |
|
brain natriuretic peptide |
4 |
|
bronchial epithelium |
4 |
|
carcinoma, hepatocellular - ethnology - genetics - pathology |
4 |
|
clinical outcome |
4 |
|
codon |
4 |
|
colonization |
4 |
|
continuous positive airway pressure |
4 |
|
coriolus versicolor |
4 |
|
cpap |
4 |
|
cpap treatment |
4 |
|
deoxyribonucleases, type ii site-specific |
4 |
|
double-blind method |
4 |
|
egfr-tki |
4 |
|
exacerbation |
4 |
|
fatty acid-binding proteins - blood |
4 |
|
gastric-acid suppressing agents |
4 |
|
gemcitabine |
4 |
|
gene expression regulation |
4 |
|
genes, p53 |
4 |
|
genetics |
4 |
|
glycosylation end products, advanced - blood |
4 |
|
hematological toxicity |
4 |
|
hypertension |
4 |
|
immunohistochemistry |
4 |
|
immunosuppressant therapy |
4 |
|
incident type 2 diabetes |
4 |
|
influenza |
4 |
|
inhaled corticosteroid |
4 |
|
insulin - metabolism |
4 |
|
insulin resistance |
4 |
|
insulin resistance - physiology |
4 |
|
insulin sensitivity |
4 |
|
invasive mechanical ventilation |
4 |
|
liver neoplasms - ethnology - genetics - pathology |
4 |
|
low risk |
4 |
|
maintenance chemotherapy |
4 |
|
metabolic syndrome x - metabolism |
4 |
|
nephrotoxicity |
4 |
|
nicotine |
4 |
|
nicotinic acetylcholine receptor |
4 |
|
non-cystic fibrosis bronchiectasis |
4 |
|
non-diabetic men |
4 |
|
organizing pneumonia |
4 |
|
osa |
4 |
|
oxygen - metabolism |
4 |
|
palliative treatment |
4 |
|
pilot projects |
4 |
|
plasma dna |
4 |
|
point mutation |
4 |
|
polysaccharide peptides (psp) |
4 |
|
polysomnography - methods |
4 |
|
proteoglycans - therapeutic use |
4 |
|
pseudomonas aeruginosa |
4 |
|
quantitative polymerase chain reaction |
4 |
|
risk factor |
4 |
|
screening |
4 |
|
second line chemotherapy |
4 |
|
sequence analysis, dna |
4 |
|
severity of sleep disordered breathing |
4 |
|
sleep apnea syndromes - blood - physiopathology |
4 |
|
sleep apnea, obstructive - blood - diagnosis |
4 |
|
sleep apnea, obstructive - blood - physiopathology - therapy |
4 |
|
stage i non-small cell carcinoma of lung |
4 |
|
streptococcus pneumoniae |
4 |
|
survival |
4 |
|
survival outcomes |
4 |
|
treatment |
4 |
|
troponin |
4 |
|
5-fluorouracil |
3 |
|
adenocarcinoma - complications - diagnosis - ethnology |
3 |
|
adenocarcinoma - etiology - genetics - pathology |
3 |
|
adenocarcinoma - genetics - pathology |
3 |
|
adipocyte fatty acid–binding protein |
3 |
|
airflow obstruction |
3 |
|
alectinib |
3 |
|
algorithms |
3 |
|
allelic imbalance |
3 |
|
array cgh |
3 |
|
bevacizumab |
3 |
|
bleeding |
3 |
|
blood glucose - metabolism |
3 |
|
bone metastasis |
3 |
|
brain neoplasms - complications - pathology - secondary |
3 |
|
breast carcinoma |
3 |
|
breezhaler™ |
3 |
|
bronchi - cytology |
3 |
|
bronchi - pathology |
3 |
|
bronchial epithelial cells |
3 |
|
bronchial neoplasms - diagnosis - pathology |
3 |
|
bronchoscopy - methods |
3 |
|
capecitabine |
3 |
|
carcinoma, large cell - complications - diagnosis - ethnology |
3 |
|
carcinoma, non-small-cell lung - complications - pathology - secondary |
3 |
|
carcinoma, non-small-cell lung - genetics - metabolism |
3 |
|
carcinoma, squamous cell - complications - diagnosis - ethnology |
3 |
|
cardiac patient |
3 |
|
case report |
3 |
|
cell line |
3 |
|
cell line, tumor |
3 |
|
chrna7 |
3 |
|
chromosome aberrations |
3 |
|
cigarette smoke |
3 |
|
clinical profiles |
3 |
|
clinical tool |
3 |
|
conscious sedation |
3 |
|
cryptococcosis - diagnosis - epidemiology |
3 |
|
cryptococcus neoformans |
3 |
|
deoxycytidine - analogs & derivatives - therapeutic use |
3 |
|
diabetes mellitus, type 2 - blood - complications - epidemiology |
3 |
|
diagnostic value |
3 |
|
earache - etiology |
3 |
|
eef1a2 |
3 |
|
egfr signaling |
3 |
|
ehr |
3 |
|
elderly |
3 |
|
electronic health record |
3 |
|
ellipta™ |
3 |
|
epithelial cells - drug effects - metabolism - physiology |
3 |
|
fluorescence |
3 |
|
fluorouracil - analogs & derivatives - therapeutic use |
3 |
|
forced expiratory volume |
3 |
|
gene dosage |
3 |
|
gene expression regulation, neoplastic |
3 |
|
gene silencing |
3 |
|
genetic predisposition to disease - genetics |
3 |
|
genome, human |
3 |
|
genuair® |
3 |
|
in situ hybridization, fluorescence |
3 |
|
inhalation device |
3 |
|
klf6 |
3 |
|
large tumor suppressor 2 gene |
3 |
|
lung |
3 |
|
lung diseases, fungal - diagnosis - epidemiology |
3 |
|
lung neoplasms - complications - diagnosis - ethnology |
3 |
|
lung neoplasms - complications - pathology |
3 |
|
lung neoplasms - diagnosis |
3 |
|
lung neoplasms - etiology - genetics - pathology |
3 |
|
lung neoplasms - genetics - metabolism |
3 |
|
lung neoplasms - genetics - pathology |
3 |
|
lymphoepithelioma-like carcinoma |
3 |
|
malignant pleural effusion |
3 |
|
metaphase - genetics |
3 |
|
metaphase cgh |
3 |
|
microarray analysis - methods |
3 |
|
microsatellite repeats |
3 |
|
neoplasm staging |
3 |
|
nicotine - pharmacology |
3 |
|
non-smokers |
3 |
|
nucleic acid hybridization - methods |
3 |
|
oligonucleotide array sequence analysis |
3 |
|
oral appliances |
3 |
|
outcome |
3 |
|
patient education as topic |
3 |
|
pd-l1 |
3 |
|
pembrolizumab |
3 |
|
plethysmography |
3 |
|
pleural drainage |
3 |
|
pleurodesis |
3 |
|
pneumonia |
3 |
|
polymerase chain reaction |
3 |
|
pre-invasive lesion |
3 |
|
pulmonary function testing |
3 |
|
receptors, nicotinic - biosynthesis - genetics |
3 |
|
respiratory diseases |
3 |
|
retrognathism |
3 |
|
reverse transcriptase polymerase chain reaction |
3 |
|
review |
3 |
|
rna, messenger - biosynthesis - genetics |
3 |
|
salvage therapy |
3 |
|
semirigid pleuroscopy |
3 |
|
severe obstructive sleep apnea |
3 |
|
sleep apnea, obstructive - diagnosis - epidemiology - etiology |
3 |
|
sleep apnea, obstructive - therapy |
3 |
|
smoking - adverse effects - genetics |
3 |
|
smoking - adverse effects - genetics - metabolism |
3 |
|
spirometry |
3 |
|
thoracentesis |
3 |
|
tobacco |
3 |
|
tomography, x-ray computed |
3 |
|
tomography, x-ray computed - methods |
3 |
|
tumor cells, cultured |
3 |
|
tyrosine kinase inhibitor |
3 |
|
validation |
3 |
|
albumin |
2 |
|
asia - epidemiology |
2 |
|
asian continental ancestry group - statistics & numerical data |
2 |
|
asthma - epidemiology - physiopathology |
2 |
|
bronchiolitis obliterans |
2 |
|
carcinoma, adenosquamous - genetics |
2 |
|
cardiovascular disease |
2 |
|
cerebral hemorrhage - blood - complications |
2 |
|
cerebral infarction - blood - complications |
2 |
|
chemical pleurodesis |
2 |
|
cholesterol - blood |
2 |
|
cholesterol, hdl - blood |
2 |
|
circulating tumor dna (ctdna) |
2 |
|
comorbidity |
2 |
|
computer assisted tomography |
2 |
|
continuous manufacturing |
2 |
|
craniofacial abnormalities - complications |
2 |
|
diabetes complications |
2 |
|
diabetes mellitus |
2 |
|
diabetes mellitus - diagnosis - epidemiology |
2 |
|
dna methylation |
2 |
|
dry powder inhaler |
2 |
|
epidermal growth factor receptor (egfr) |
2 |
|
erlotinib |
2 |
|
extracellular vesicles |
2 |
|
gene expression profiling - methods |
2 |
|
glucocorticoids - administration and dosage - therapeutic use |
2 |
|
glucose tolerance test |
2 |
|
graft versus host reaction |
2 |
|
haemorrhagic stroke |
2 |
|
hematopoietic stem cell transplantation |
2 |
|
hippo |
2 |
|
human |
2 |
|
hypoxia |
2 |
|
impaired glucose tolerance |
2 |
|
india |
2 |
|
intratumoural heterogeneity |
2 |
|
ischaemic stroke |
2 |
|
large tumour suppressor (lats) |
2 |
|
ldct screening |
2 |
|
letter |
2 |
|
longitudinal assessment |
2 |
|
lung neoplasms - genetics |
2 |
|
nanoagglomerate |
2 |
|
nanoparticles |
2 |
|
nonsmokers |
2 |
|
pleural vent™ |
2 |
|
pneumothorax |
2 |
|
priority journal |
2 |
|
programmed death‐ligand 1 |
2 |
|
promoter regions, genetic - genetics |
2 |
|
protein |
2 |
|
pulmonary drug delivery |
2 |
|
remdesivir |
2 |
|
rhinitis |
2 |
|
rhinitis, allergic, perennial - drug therapy - epidemiology |
2 |
|
rhinitis, allergic, seasonal - drug therapy - epidemiology |
2 |
|
sleep apnea syndrome |
2 |
|
sleep apnea, obstructive - complications - epidemiology - ethnology - therapy |
2 |
|
sleep apnoea |
2 |
|
sleep disordered breathing |
2 |
|
t790m |
2 |
|
tki-resistance |
2 |
|
toxic megacolon |
2 |
|
triglycerides - blood |
2 |
|
tumor burden |
2 |
|
adenocarcinoma - etiology |
1 |
|
adenoma - drug therapy |
1 |
|
air pollution |
1 |
|
asia-pacific |
1 |
|
asian-pacific region |
1 |
|
asia‐pacific region |
1 |
|
cancer |
1 |
|
carcinogens - toxicity |
1 |
|
cell transformation, neoplastic - pathology |
1 |
|
chronic effect of tb |
1 |
|
chronic obstructive pulmonary disease (copd) |
1 |
|
climate change |
1 |
|
clinical applications |
1 |
|
disease models, animal |
1 |
|
dyspnoea |
1 |
|
electronic cigarette |
1 |
|
electronic cigarettes |
1 |
|
electronic nicotine delivery system |
1 |
|
equal access |
1 |
|
evidence base |
1 |
|
exacerbations |
1 |
|
family medicine |
1 |
|
gold classification |
1 |
|
guideline adherence |
1 |
|
health care resources |
1 |
|
healthcare equity |
1 |
|
her2 mutations |
1 |
|
immune checkpoint inhibitor |
1 |
|
impact |
1 |
|
indwelling pleural catheter |
1 |
|
low-dose ct |
1 |
|
lung cancer risk |
1 |
|
lung cancer treatment |
1 |
|
lung function test |
1 |
|
malignant |
1 |
|
medications |
1 |
|
molecular pathology |
1 |
|
molecular targets |
1 |
|
molecular testing |
1 |
|
multidisciplinary team meeting |
1 |
|
mutation |
1 |
|
named patient use |
1 |
|
nicotine delivery devices |
1 |
|
nodules |
1 |
|
noninvasive ventilation |
1 |
|
non‐small cell lung cancer |
1 |
|
oncogene |
1 |
|
oncology |
1 |
|
personalized treatment |
1 |
|
pleural effusion |
1 |
|
population-based |
1 |
|
prevention |
1 |
|
primary care |
1 |
|
programme evaluation |
1 |
|
protocol |
1 |
|
quality of life (qol) |
1 |
|
randomised trial |
1 |
|
respirology |
1 |
|
shared care model |
1 |
|
smoking cessation |
1 |
|
survey |
1 |
|
targeted therapy |
1 |
|
tobacco products |
1 |
|
tobacco smoking |
1 |
|
tumor immune microenvironment |
1 |
|
tumour suppressor gene |
1 |
|
uncommon egfr mutations |
1 |
